Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Guoxiao Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9061-4203; OpenAlex author ID A5001632337. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2021: 2 papers · 2022: 2 papers · 2023: 4 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 11

  1. Early-Onset Pancreatic Ductal Adenocarcinoma: Clinical Features, Genomic Landscape, and Treatment-Mediated Survival Advantage Co-author DOI 10.21203/rs.3.rs-9647757/v1↗
  2. A practical distribution pattern of α-SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102282↗
  3. Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s41467-025-57520-3↗
  4. Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. Co-author DOI 10.1093/bjs/znac457↗
  5. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-023-11181-x↗
  6. Combined utility of Ki-67 index and tumor grade to stratify patients with pancreatic ductal adenocarcinoma who underwent upfront surgery. Co-author DOI 10.1186/s12893-023-02256-4↗
  7. Systemic Immune-Inflammation Index After Neoadjuvant Therapy Predicts the Pathological Response in Patients with Resected Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-2856912/v1↗
  8. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. Co-author DOI 10.1016/j.ijsu.2022.106786↗
  9. Negative p53 Expression Confers Worse Prognosis in Patients With Resected Pancreatic Ductal Adenocarcinoma: Research Focused on Reinterpretation of Immunohisto… Co-author DOI 10.1097/mpa.0000000000002175↗
  10. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08380-9↗
  11. The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients. Co-author DOI 10.3389/fonc.2021.717989↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaoyi Yin · 10 shared papers, 2021–2026 · strength 1.78
  2. Shiwei Guo · 10 shared papers, 2021–2025 · strength 1.52
  3. Gang Jin · 8 shared papers, 2021–2026 · strength 1.39
  4. Suizhi Gao · 8 shared papers, 2021–2025 · strength 1.17
  5. Xiaohan Shi · 8 shared papers, 2021–2025 · strength 1.17
  6. Kailian Zheng · 6 shared papers, 2021–2025 · strength 0.89
  7. Bo Li · 6 shared papers, 2021–2023 · strength 0.87
  8. Shuo Shen · 6 shared papers, 2021–2023 · strength 0.81
  9. Xiongfei Xu · 5 shared papers, 2021–2025 · strength 0.72
  10. Lingyu Zhu · 3 shared papers, 2023 · strength 0.45
  11. Jian Wang · 3 shared papers, 2022–2023 · strength 0.45
  12. Gang Li · 3 shared papers, 2021–2025 · strength 0.39
  13. Meilong Shi · 2 shared papers, 2025 · strength 0.36
  14. Huan Wang · 1 shared paper, 2026 · strength 0.36
  15. Gang Jin · 2 shared papers, 2022–2025 · strength 0.33
  16. Bin Song · 2 shared papers, 2023–2025 · strength 0.29
  17. Wei Jing · 2 shared papers, 2021–2025 · strength 0.26
  18. Zhuo Shao · 2 shared papers, 2021–2023 · strength 0.23
  19. Bo Li · 1 shared paper, 2025 · strength 0.20
  20. Gang Y Jin · 1 shared paper, 2023 · strength 0.16
  21. Hui Jiang · 1 shared paper, 2023 · strength 0.16
  22. Chunming Zhang · 1 shared paper, 2025 · strength 0.16
  23. Yunguang Li · 1 shared paper, 2025 · strength 0.16
  24. Dong Gao · 1 shared paper, 2025 · strength 0.16
  25. Yang Wang · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.